Ethris Revenue and Competitors
Estimated Revenue & Valuation
- Ethris's estimated annual revenue is currently $12.2M per year.
- Ethris's estimated revenue per employee is $155,000
Employee Data
- Ethris has 79 Employees.
- Ethris grew their employee count by 46% last year.
Ethris Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Ethris?
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients' cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.
keywords:N/A
N/A
Total Funding
79
Number of Employees
$12.2M
Revenue (est)
46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ethris News
Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech,...
Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech,...
Unlike marketed mRNA vaccines, which are delivered via an injection, Ethris' therapies are designed to be inhalable. The company uses lipid...
Other Companies in Planegg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.4M | 93 | N/A | N/A |
#2 | $32.6M | 210 | 8% | N/A |
#3 | $116M | 462 | 28% | N/A |
#4 | $162.7M | 1219 | 33% | N/A |